Adlai Nortye In-Licenses Oncolytic's Cancer Drug in $86.6 Million Deal

Adlai Nortye, a Hangzhou company, entered a $86.6 million iin-licensing agreement to develop and market a novel immuno-oncolytic virus in Greater China that was discovered by Canada 's Oncolytics Biotech ® . Reolysin ® is an intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems. Oncolytics plans a US Phase III trial of Reolysin in patients with HR+/HER2 metastatic breast cancer. Adlai Nortye will be responsible for all China clinical development of the candidate. More details.... Stock Symbol: (TSX: ONC) Share this with colleagues: // //